Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Activity of the investigational fluoroquinolone finafloxacin and seven other antimicrobial agents against 114 obligately anaerobic bacteria.

Genzel GH, Stubbings W, Stîngu CS, Labischinski H, Schaumann R.

Int J Antimicrob Agents. 2014 Nov;44(5):420-3. doi: 10.1016/j.ijantimicag.2014.07.006. Epub 2014 Aug 19.

PMID:
25264128
2.

Uniformity of glycyl bridge lengths in the mature cell walls of fem mutants of methicillin-resistant Staphylococcus aureus.

Sharif S, Kim SJ, Labischinski H, Chen J, Schaefer J.

J Bacteriol. 2013 Apr;195(7):1421-7. doi: 10.1128/JB.01471-12. Epub 2013 Jan 18.

3.

In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions.

Stubbings W, Leow P, Yong GC, Goh F, Körber-Irrgang B, Kresken M, Endermann R, Labischinski H.

Antimicrob Agents Chemother. 2011 Sep;55(9):4394-7. doi: 10.1128/AAC.00833-10. Epub 2011 Jun 27.

4.

Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.

Patel H, Andresen A, Vente A, Heilmann HD, Stubbings W, Seiberling M, Lopez-Lazaro L, Pokorny R, Labischinski H.

Antimicrob Agents Chemother. 2011 Sep;55(9):4386-93. doi: 10.1128/AAC.00832-10. Epub 2011 Jun 27.

5.

Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations of defined mechanisms of fluoroquinolone resistance.

Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P.

J Antimicrob Chemother. 2010 Dec;65(12):2530-3. doi: 10.1093/jac/dkq375. Epub 2010 Oct 12.

PMID:
20940181
6.

Characterization of peptidoglycan in fem-deletion mutants of methicillin-resistant Staphylococcus aureus by solid-state NMR.

Sharif S, Kim SJ, Labischinski H, Schaefer J.

Biochemistry. 2009 Apr 14;48(14):3100-8. doi: 10.1021/bi801750u.

7.

Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.

Wecke T, Zühlke D, Mäder U, Jordan S, Voigt B, Pelzer S, Labischinski H, Homuth G, Hecker M, Mascher T.

Antimicrob Agents Chemother. 2009 Apr;53(4):1619-23. doi: 10.1128/AAC.01046-08. Epub 2009 Jan 21.

8.

The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate.

Schneider T, Gries K, Josten M, Wiedemann I, Pelzer S, Labischinski H, Sahl HG.

Antimicrob Agents Chemother. 2009 Apr;53(4):1610-8. doi: 10.1128/AAC.01040-08. Epub 2009 Jan 21.

9.

New antibiotics for antibiotic-resistant bacteria.

Stubbings W, Labischinski H.

F1000 Biol Rep. 2009 May 28;1:40. doi: 10.3410/B1-40.

10.

Prospects and challenges in anti-infective research and development: new drugs and approaches.

Labischinski H, Ruebsamen-Waigmann H.

Curr Opin Pharmacol. 2008 Oct;8(5):519-21. doi: 10.1016/j.coph.2008.09.006. Epub 2008 Oct 17. No abstract available.

PMID:
18848903
11.

In vitro and in vivo validation of ligA and tarI as essential targets in Staphylococcus aureus.

Streker K, Schäfer T, Freiberg C, Brötz-Oesterhelt H, Hacker J, Labischinski H, Ohlsen K.

Antimicrob Agents Chemother. 2008 Dec;52(12):4470-4. doi: 10.1128/AAC.00548-07. Epub 2008 Sep 22.

12.

Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.

Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, Rubio A, Parent L, Ednie L, Koeth L, Bogdanovich T, Appelbaum PC.

Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8. Epub 2007 Jul 9.

13.

Medicinal chemistry optimization of acyldepsipeptides of the enopeptin class antibiotics.

Hinzen B, Raddatz S, Paulsen H, Lampe T, Schumacher A, Häbich D, Hellwig V, Benet-Buchholz J, Endermann R, Labischinski H, Brötz-Oesterhelt H.

ChemMedChem. 2006 Jul;1(7):689-93. No abstract available.

PMID:
16902918
14.

Dysregulation of bacterial proteolytic machinery by a new class of antibiotics.

Brötz-Oesterhelt H, Beyer D, Kroll HP, Endermann R, Ladel C, Schroeder W, Hinzen B, Raddatz S, Paulsen H, Henninger K, Bandow JE, Sahl HG, Labischinski H.

Nat Med. 2005 Oct;11(10):1082-7. Epub 2005 Oct 2. Erratum in: Nat Med. 2005 Dec;11(12):1361.

PMID:
16200071
15.

Novel anti-staphylococcal targets and compounds.

Labischinski H, Ehlert K, Wieland B.

Expert Opin Investig Drugs. 1998 Aug;7(8):1245-56.

PMID:
15992028
16.

Staphylococcus aureus NfrA (SA0367) is a flavin mononucleotide-dependent NADPH oxidase involved in oxidative stress response.

Streker K, Freiberg C, Labischinski H, Hacker J, Ohlsen K.

J Bacteriol. 2005 Apr;187(7):2249-56.

17.

The impact of transcriptome and proteome analyses on antibiotic drug discovery.

Freiberg C, Brötz-Oesterhelt H, Labischinski H.

Curr Opin Microbiol. 2004 Oct;7(5):451-9. Review.

PMID:
15451499
18.

Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.

Thomson CJ, Power E, Ruebsamen-Waigmann H, Labischinski H.

Curr Opin Microbiol. 2004 Oct;7(5):445-50. Review.

PMID:
15451498
19.

Bacterial proteomics and its role in antibacterial drug discovery.

Brötz-Oesterhelt H, Bandow JE, Labischinski H.

Mass Spectrom Rev. 2005 Jul-Aug;24(4):549-65. Review.

PMID:
15389844
20.

Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Koehl JL, Muthaiyan A, Jayaswal RK, Ehlert K, Labischinski H, Wilkinson BJ.

Antimicrob Agents Chemother. 2004 Oct;48(10):3749-57.

21.

Specific and potent inhibition of NAD+-dependent DNA ligase by pyridochromanones.

Brötz-Oesterhelt H, Knezevic I, Bartel S, Lampe T, Warnecke-Eberz U, Ziegelbauer K, Häbich D, Labischinski H.

J Biol Chem. 2003 Oct 10;278(41):39435-42. Epub 2003 Jul 15.

22.

Proteomic approach to understanding antibiotic action.

Bandow JE, Brötz H, Leichert LI, Labischinski H, Hecker M.

Antimicrob Agents Chemother. 2003 Mar;47(3):948-55.

23.

Molecular characterization of an atl null mutant of Staphylococcus aureus.

Takahashi J, Komatsuzawa H, Yamada S, Nishida T, Labischinski H, Fujiwara T, Ohara M, Yamagishi J, Sugai M.

Microbiol Immunol. 2002;46(9):601-12.

24.

Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus.

Geisel R, Schmitz FJ, Fluit AC, Labischinski H.

Eur J Clin Microbiol Infect Dis. 2001 Oct;20(10):685-97. Review.

PMID:
11757969
25.

Increased glycan chain length distribution and decreased susceptibility to moenomycin in a vancomycin-resistant Staphylococcus aureus mutant.

Komatsuzawa H, Ohta K, Yamada S, Ehlert K, Labischinski H, Kajimura J, Fujiwara T, Sugai M.

Antimicrob Agents Chemother. 2002 Jan;46(1):75-81.

26.

New antibiotics.

Labischinski H.

Int J Med Microbiol. 2001 Nov;291(5):317-8. No abstract available.

PMID:
11727814
27.

Synthesis and biological evaluation of vancomycin dimers with potent activity against vancomycin-resistant bacteria: target-accelerated combinatorial synthesis.

Nicolaou KC, Hughes R, Cho SY, Winssinger N, Labischinski H, Endermann R.

Chemistry. 2001 Sep 3;7(17):3824-43.

PMID:
11575783
28.

Solid- and solution-phase synthesis of vancomycin and vancomycin analogues with activity against vancomycin-resistant bacteria.

Nicolaou KC, Cho SY, Hughes R, Winssinger N, Smethurst C, Labischinski H, Endermann R.

Chemistry. 2001 Sep 3;7(17):3798-823.

PMID:
11575782
29.

Cloning and sequencing of the gene, fmtC, which affects oxacillin resistance in methicillin-resistant Staphylococcus aureus.

Komatsuzawa H, Ohta K, Fujiwara T, Choi GH, Labischinski H, Sugai M.

FEMS Microbiol Lett. 2001 Sep 11;203(1):49-54.

30.

Cell wall targets in methicillin-resistant staphylococci.

Labischinski H, Johannsen L.

Drug Resist Updat. 1999 Oct;2(5):319-325.

PMID:
11504506
31.

Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria.

Freiberg C, Wieland B, Spaltmann F, Ehlert K, Brötz H, Labischinski H.

J Mol Microbiol Biotechnol. 2001 Jul;3(3):483-9.

PMID:
11361082
32.

Coprinol, a new antibiotic cuparane from a Coprinus species.

Johansson M, Sterner O, Labischinski H, Anke T.

Z Naturforsch C J Biosci. 2001 Jan-Feb;56(1-2):31-4.

PMID:
11302209
33.

A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates.

Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RS.

Antimicrob Agents Chemother. 2001 Jan;45(1):280-7.

34.

Target-Accelerated Combinatorial Synthesis and Discovery of Highly Potent Antibiotics Effective Against Vancomycin-Resistant Bacteria.

Nicolaou KC, Hughes R, Cho SY, Winssinger N, Smethurst C, Labischinski H, Endermann R.

Angew Chem Int Ed Engl. 2000 Nov 3;39(21):3823-3828. doi: 10.1002/1521-3773(20001103)39:21<3823::AID-ANIE3823>3.0.CO;2-3. No abstract available.

PMID:
29711708
35.

The fib locus in Streptococcus pneumoniae is required for peptidoglycan crosslinking and PBP-mediated beta-lactam resistance.

Weber B, Ehlert K, Diehl A, Reichmann P, Labischinski H, Hakenbeck R.

FEMS Microbiol Lett. 2000 Jul 1;188(1):81-5.

36.

Characterization of fmtA, a gene that modulates the expression of methicillin resistance in Staphylococcus aureus.

Komatsuzawa H, Ohta K, Labischinski H, Sugai M, Suginaka H.

Antimicrob Agents Chemother. 1999 Sep;43(9):2121-5.

37.

The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation.

Rohrer S, Ehlert K, Tschierske M, Labischinski H, Berger-Bächi B.

Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9351-6.

38.
39.

Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.

Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K.

J Antimicrob Chemother. 1998 Sep;42(3):315-20.

PMID:
9786471
40.

Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.

Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu K.

J Antimicrob Chemother. 1998 Aug;42(2):199-209.

PMID:
9738837
41.

The targeting of factors necessary for expression of methicillin resistance in staphylococci.

Labischinski H, Ehlert K, Berger-Bächi B.

J Antimicrob Chemother. 1998 Jun;41(6):581-4. Review. No abstract available.

PMID:
9687095
42.

[Increase of non-amidated muropeptides in the cell wall of vancomycin-resistant Staphylococcus aureus (VRSA) strain Mu50].

Hanaki H, Labischinski H, Inaba Y, Hiramatsu K.

Jpn J Antibiot. 1998 Apr;51(4):272-80. Japanese.

PMID:
9644600
43.

[Mechanism of vancomycin resistance in MRSA strain Mu50].

Hanaki H, Labischinski H, Sasaki K, Kuwahara-Arai K, Inaba Y, Hiramatsu K.

Jpn J Antibiot. 1998 Mar;51(3):237-47. Japanese.

PMID:
9597552
44.

Improved high-performance liquid chromatographic separation of peptidoglycan isolated from various Staphylococcus aureus strains for mass spectrometric characterization.

Roos M, Pittenauer E, Schmid E, Beyer M, Reinike B, Allmaier G, Labischinski H.

J Chromatogr B Biomed Sci Appl. 1998 Feb 13;705(2):183-92.

PMID:
9521554
46.

Small-angle X-ray scattering analysis of pneumococcal lipoteichoic acid phase structure.

Fischer W, Markwitz S, Labischinski H.

Eur J Biochem. 1997 Mar 15;244(3):913-7.

47.

Identification and mapping of new chromosomal sites affecting response to beta-lactams in Staphylococcus aureus.

Vasilieva E, Labischinski H, Berger-Bächi B.

Int J Antimicrob Agents. 1997 Feb;8(1):13-21.

PMID:
18611780
48.
49.

Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target?

Kopp U, Roos M, Wecke J, Labischinski H.

Microb Drug Resist. 1996 Spring;2(1):29-41.

PMID:
9158720
50.

FemA of Staphylococcus aureus: isolation and immunodetection.

Johnson S, Krüger D, Labischinski H.

FEMS Microbiol Lett. 1995 Oct 15;132(3):221-8.

PMID:
7590176

Supplemental Content

Loading ...
Support Center